Primary Menu

Month December 2014

Biopharmaceutical companies generate billions in economic activity for New Jersey, but don’t expect their latest, most high-profile venture — tackling the Ebola epidemic — to add much to their bottom line.

Industry leaders say they have a greater goal in mind.

“The real purpose is not to make money or not lose money. The real purpose is to respond to the public health need,” said Dr. Mark Feinberg, chief public health and science officer for vaccines at Merck & Co. in Kenilworth.